Catalyst Events and Market Watch Significant upcoming catalyst events include the phase [name] readout of Eli Lillys glipron, which will indicate the efficacy of oral GLP-1s, followed by Pfizers glipron and other oral GLP-1s by 2028
Common and Rare Adverse Effects of GLP-1 Agonists While highly effective, GLP-1 receptor agonists can cause temporary side effects as your body adjusts to the metabolic changes
Some people also experience dizziness, increased heart rate, infections, headaches, upset stomach or redness or itchiness at the injection site
[1] [2] Fasting plasma concentrations of biologically active GLP-1 range between 0 and 15 pmol/L in humans and are increased 2- to 3-fold upon food consumption depending on meal size and nutrient composition
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control
Emerging Trends and Market Dynamics The GLP-1 market is poised for significant growth, with Novo Nordisk and Eli Lilly set to launch new injectables and oral formulations
